ABCL Share Price Performance

ABCL Community Fair Values

AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
Key Takeaways Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules. Integrated clinical manufacturing capabilities will likely boost efficiency and margins, while strong liquidity supports long-term pipeline development.
US$9.14
FV
53.6% undervalued intrinsic discount
60.00%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
40users have followed this narrative
Updated narrative

View all narratives

Recent ABCL News & Updates

No updates

AbCellera Biologics Inc. Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

Aug 07, 2025

Earnings per share (EPS): -0.56
Gross Margin: -637.51%
Net Profit Margin: -726.26%
Debt/Equity Ratio: 0%

View full report ›

AbCellera Biologics Inc. Competitors

View more competitors

About ABCL

Founded: 2012
Employees: 596
CEO: Carl Hansen
WebsiteView website: www.abcellera.com

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Canadian Market Performance

7 Days: -1.7%
3 Months: 8.2%
1 Year: 18.6%
Year to Date: 8.7%

Over the last 7 days, the market has dropped 1.8%, driven by declines in every sector, especially the Financials sector. In contrast to the last week, the market is actually up 19% over the past year. As for the next few years, earnings are expected to grow by 12% per annum. Market details ›

💥 How Agentic AI Could Change Every Industry

Richard Bowman

August 2025

This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.

Last Week

AbCellera Biologics Stock Price